Development Strategy

Our approval pathway in dogs has a ~90% overlap with IND enabling studies in humans. We have partnered with Phibro Animal Health for the development and commercialization of a gene therapy for Mitral Valve Disease (MVD), providing an early revenue stream to further develop our human clinical programs.